Cargando…

CAR-NK Cells Targeting Sars-Cov-2 Glycosites As COVID-19 Treatment

Introduction: Banana Lectin (BanLec) is a glycoprotein-binding lectin derived from banana fruit that has antiviral activity. BanLec binds high mannose glycans expressed on the viral envelopes of HIV, Ebola, influenza, and coronaviruses. BanLec mitogenicity can be divorced from antiviral activity via...

Descripción completa

Detalles Bibliográficos
Autores principales:	Christodoulou, Ilias, Rahnama, Ruyan, Ravich, Wesley J., Seo, Jaesung, Zolov, Sergey, Marple, Andrew, Markovitz, David M, Bonifant, Challice L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology. Published by Elsevier Inc. 2021
Materias:	703.Cellular Immunotherapies: Basic and Translational
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701694/ http://dx.doi.org/10.1182/blood-2021-146865

Ejemplares similares

Glycoprotein Targeted CAR-NK Cells for the Treatment of SARS-CoV-2 Infection
por: Christodoulou, Ilias, et al.
Publicado: (2021)

Loss of an Immunodominant HLA-Α *01:01 Restricted Epitope for CD8+ Cytotoxic T Lymphocytes (CTLs) in the Delta Variant of COVID-19: An Example of Immunologic Escape and Implications for Immunologic Treatment
por: Flomenberg, Neal, et al.
Publicado: (2021)

Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities
por: Christodoulou, Ilias, et al.
Publicado: (2021)

Targeting of Nrf2 improves antitumoral responses by human NK cells, TIL and CAR T cells during oxidative stress
por: Renken, Stefanie, et al.
Publicado: (2022)

Using Allogeneic, Off-the-Shelf, Sars-Cov-2-Specific T Cells to Treat High Risk Patients with COVID-19
por: Vasileiou, Spyridoula, et al.
Publicado: (2020)

Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) Mediate Protection Against Influenza A Viral Infection
por: He, Shuyang, et al.
Publicado: (2020)

Toxicity and management in CAR T-cell therapy
por: Bonifant, Challice L, et al.
Publicado: (2016)

Enhancing co-stimulation of CAR T cells to improve treatment outcomes in solid cancers
por: Harrison, Aaron J, et al.
Publicado: (2021)

CAR-T cells leave the comfort zone: current and future applications beyond cancer
por: Mazzi, Mariana Torres, et al.
Publicado: (2020)

IMMU-20. EVALUATION OF CAR T CELLS IN EPENDYMOMA
por: Nellan, Anandani, et al.
Publicado: (2020)

PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations
por: Fabian, Kellsye P, et al.
Publicado: (2020)

Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
por: Qu, Xiaoyan, et al.
Publicado: (2022)

IMMU-20. Effective CAR-T cell medulloblastoma therapy in an immunocompetent mouse model
por: Tsahouridis, Rania, et al.
Publicado: (2022)

Modulating TNFα activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia
por: Ataca Atilla, Pinar, et al.
Publicado: (2020)

Novel banana lectin CAR-T cells to target pancreatic tumors and tumor-associated stroma
por: McKenna, Mary K, et al.
Publicado: (2023)

COVID-19 Vaccination and Anti-CD19 CAR T Cell-Induced B Cell Aplasia
por: Sookaromdee, Pathum, et al.
Publicado: (2022)

TGFβ drives NK cell metabolic dysfunction in human metastatic breast cancer
por: Slattery, Karen, et al.
Publicado: (2021)

Fulvestrant increases the susceptibility of enzalutamide-resistant prostate cancer cells to NK-mediated lysis
por: Dahut, Madeline, et al.
Publicado: (2023)

IMMU-11. LOCOREGIONAL DELIVERY OF TRANSIENT GD2 CAR T CELLS FOR SAFE AND EFFECTIVE TREATMENT OF DIPG
por: Foster, Jessica, et al.
Publicado: (2020)

IMMU-23. Novel gene-edited CAR-T cell therapy against Diffuse Intrinsic Pontine Glioma
por: Balakrishnan, Ilango, et al.
Publicado: (2022)

Improving the anti-acute myeloid leukemia activity of CD123-specific engager T cells by MyD88 and CD40 co-stimulation
por: Vaidya, Abishek, et al.
Publicado: (2022)

Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients
por: Itzhaki, Orit, et al.
Publicado: (2020)

Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation
por: Holland, Elizabeth M, et al.
Publicado: (2022)

IMMU-16. INTRA-TUMOURAL IL-12 DELIVERY ENABLES CAR T-CELL IMMUNOTHERAPY FOR HIGH-GRADE GLIOMA
por: Agliardi, Giulia, et al.
Publicado: (2020)

IMMU-22. Safely targeting GD2 in thalamic diffuse midline glioma with mRNA CAR T cells
por: Foster, Jessica, et al.
Publicado: (2022)

GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape
por: Caforio, Matteo, et al.
Publicado: (2021)

IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: implications for antimetastatic treatment
por: Desbois, Mélanie, et al.
Publicado: (2020)

Harnessing radiotherapy-induced NK-cell activity by combining DNA damage–response inhibition and immune checkpoint blockade
por: Patin, Emmanuel C, et al.
Publicado: (2022)

Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2
por: Pellizzari, Giulia, et al.
Publicado: (2021)

Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in acute myeloid leukemia
por: Sánchez Martínez, Diego, et al.
Publicado: (2022)

Galectin-9 expression defines exhausted T cells and impaired cytotoxic NK cells in patients with virus-associated solid tumors
por: Okoye, Isobel, et al.
Publicado: (2020)

IMMU-02. CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL NEUROTOXICITY CORRELATES WITH PRETREATMENT AND ACUTE CSF NEUROFILAMENT LIGHT CHAIN (NFL) LEVELS
por: Gust, Juliane, et al.
Publicado: (2020)

Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3
por: Chung, Young Min, et al.
Publicado: (2021)

Mapping Yeast N-Glycosites with Isotopically Recoded Glycans
por: Breidenbach, Mark A., et al.
Publicado: (2012)

Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed/refractory B-ALL
por: Song, Fengmei, et al.
Publicado: (2023)

Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies
por: Shalabi, Haneen, et al.
Publicado: (2020)

Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas
por: Judge, Sean J, et al.
Publicado: (2020)

IMMU-14. SynNotch chimeric antigen receptor (CAR) T-cells as a potential treatment for diffuse intrinsic pontine glioma (DIPG)/diffuse midline glioma (DMG)
por: Ferrerosa, Lauren, et al.
Publicado: (2022)

Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma
por: Wiedmeier, Julia E., et al.
Publicado: (2021)

IMMU-05. B7-H3-SPECIFIC CAR T CELLS HAVE POTENT ANTI-TUMOR ACTIVITY IN THE GL261 IMMUNE-COMPETENT MURINE BRAIN TUMOR MODEL
por: Haydar, Dalia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6p6fs50vda1qe0frt7llu5utmq